Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVA21/pembrolizumab · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| CVA21/pembrolizumab | EXPERIMENTAL | CVA21/pembrolizumab |
| Name | Type | Description |
|---|---|---|
| CVA21/pembrolizumab | BIOLOGICAL | - |
Inclusion Criteria: * Histologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma. * VLA009A: Locally advanced and/or metastatic disease for which curative surgery and/or radiation therapy is not possible a...
Top 20 of 84 competitors
CVA21/pembrolizumab is an investigational combination therapy being studied for the treatment of non-small cell lung cancer. It combines the monoclonal antibody pembrolizumab with CVA21, an oncolytic virus. The therapy is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CVA21/pembrolizumab is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate this combination therapy for non-small cell lung cancer and bladder cancer.
CVA21/pembrolizumab is in Phase 1 clinical development. The therapy is investigational and has not received regulatory approval. One Phase 1 trial has been completed, and the combination is being evaluated for safety and preliminary efficacy in patients with non-small cell lung cancer.
CVA21/pembrolizumab was studied in clinical trial NCT02043665, titled "CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/KEYNOTE-200)." This Phase 1 trial enrolled 85 participants and has been completed. The study was conducted in the United States, Australia, and the United Kingdom.
CVA21/pembrolizumab combines two agents: pembrolizumab, a monoclonal antibody that targets PD-1 to enhance the immune system's ability to fight cancer, and CVA21, an oncolytic virus designed to infect and destroy cancer cells. Together, they aim to stimulate an anti-tumor immune response in non-small cell lung cancer.